The Technical Analyst
XBiotech Inc [XBIT]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
XBiotech Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.73% $8.21
America/New_York / 25 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 249.89 mill |
| EPS: | -0.810 |
| P/E: | -10.14 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 30.44 mill |
| Avg Daily Volume: | 0.0731 mill |
| RATING 2024-04-25 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -10.14 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.72x |
| Company: PE -10.14 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$6.57 (-19.96%) $-1.639 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 7.56 - 8.86 ( +/- 7.97%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-03 | Simard John | Buy | 2 470 355 | Convertible Loan Agreement |
| 2023-06-23 | Waldin Jan-paul | Buy | 25 000 | Director Stock Option |
| 2023-06-23 | Libby Peter | Buy | 25 000 | Director Stock Option |
| 2023-06-23 | Macadam Donald H. | Buy | 25 000 | Director Stock Option |
| 2023-06-23 | Mckenzie W Thorpe | Buy | 25 000 | Director Stock Option |
| INSIDER POWER |
|---|
| 97.97 |
| Last 100 transactions |
| Buy: 4 116 188 | Sell: 11 979 897 |
Forecast:
16:00 - $8.20
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $8.20
Forecast 2: 16:00 - $8.20
Forecast 3: 16:00 - $8.20
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $8.21 (1.73% ) |
| Volume | 0.0460 mill |
| Avg. Vol. | 0.0731 mill |
| % of Avg. Vol | 62.91 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For XBIT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
XBIT
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Last 10 Buy Signals
Latest Press Releases
2024-01-04 09:00:00 - Press Release
Xbiotech To Begin Constructing New R&d Facility On Its 48-acre Campus
Austin, texas, jan. 04, 2024 (globe newswire) -- xbiotech inc. today announced that it plans to expand it's campus headquarters with the construction of a new, state-of-the-art research and development facility. xbiotech has received city of austin approval to begin excavation for site preparation and groundwork is expected to begin 1st quarter 2024.
2023-11-14 09:00:00 - Press Release
Dr. Alan Kivitz To Chair Xbiotech's Natrunix Program In Rheumatoid Arthritis
(phase ii multicenter study is proceeding well with high anticipation) (phase ii multicenter study is proceeding well with high anticipation)
2023-09-26 09:00:00 - Press Release
Xbiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke
Austin, texas, sept. 26, 2023 (globe newswire) -- xbiotech inc. (nasdaq: xbit) announces that hutrukin is being developed by xbiotech as a breakthrough therapy to reduce brain injury after stroke. the last subject in a randomized, open-label, placebo-controlled phase i dose escalation clinical study has been enrolled. xbiotech discovered, manufactures, and is conducting this clinical study of hutrukin.
2023-08-30 09:00:00 - Press Release
Xbiotech Announces Enrollment Completion Of Phase Ii, Placebo Controlled, Multicenter Study For Natrunix In Pancreatic Cancer
Austin, texas, aug. 30, 2023 (globe newswire) -- xbiotech inc. announced today completion of enrollment of the phase ii portion of its 1-better study—a phase i/ii randomized, double-blind, placebo-controlled clinical study for natrunix in combination with chemotherapy for treating pancreatic cancer.
2023-08-08 11:47:00 - Press Release
Xbiotech Announces First Patient Begins Novel Natrunix Therapy In Phase Ii Rheumatoid Arthritis (ra) Clinical Trial
Austin, texas, aug. 08, 2023 (globe newswire) -- xbiotech inc. (nasdaq: xbit) today began treating the first patient in a phase ii, double-blind, placebo-controlled, randomized clinical study to evaluate natrunix as a new treatment for arthritis. natrunix blocks a key cause of inflammation involved in pain and joint destruction in rheumatoid arthritis (ra).
Latest News
2024-03-07 17:51:04 - Zacks Investment Research
Don't Know Much Biology? Tips for Picking Microcap Biotech, Pharma
2022-04-28 14:56:01 - Benzinga
Why Are XBiotech Shares Trading Higher Today
The French authority has signed off XBiotech Inc's (NASDAQ: XBIT) multicenter randomized clinical study for Natrunix combined with trifluridine/tipiracil for colorectal cancer. The French National Cancer Institute (INCA) has also awarded a grant to fund all clinical costs.
2021-07-30 11:03:00 - GlobeNewsWire
XBiotech Announces Payment of Dividend to Holders of Common Stock
Company distributed USD $75 Million to Shareholders Company distributed USD $75 Million to Shareholders
2021-07-07 17:23:38 - Pulse2
XBiotech Stock Increased 7.41%: Why It Happened
The stock price of XBiotech Inc (NASDAQ: XBIT) increased by 7.41%. This is why it happened.
2021-07-06 16:30:00 - GlobeNewsWire
XBiotech Announces Dividend to Holders of Common Stock
AUSTIN, Texas, July 06, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc.'s (NASDAQ: XBIT) (“XBiotech”) Board of Directors has declared an extraordinary cash dividend of approximately $2.50 per share, or up to an aggregate of $75 million, to holders of its common stock. This one-time, special dividend will be payable on July 23, 2021 to stockholders of record at the close of business on July 16, 2021.
2021-06-30 11:46:00 - GlobeNewsWire
XBiotech Announces Receipt of $75 Million from Sale of Antibody
Company Has Now Received a Total of $750 million for Sale of Its True Human Antibody Company Has Now Received a Total of $750 million for Sale of Its True Human Antibody
2021-06-23 08:30:00 - GlobeNewsWire
XBiotech Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer
XB2001 Is a Novel Therapy that Interrupts Inflammation to Potentially Block Growth and Spread of Tumors and to Reduce Toxicity of Chemotherapy Treatment XB2001 Is a Novel Therapy that Interrupts Inflammation to Potentially Block Growth and Spread of Tumors and to Reduce Toxicity of Chemotherapy Treatment
2021-04-19 07:08:57 - Benzinga
XBiotech To Test New Drug Candidate Combined With Approved Treatment In Pancreatic Cancer
The FDA has signed off Phase 1/2 clinical study to evaluate XBiotech Inc's (NASDAQ: XBIT) XB2001 when added to the ONIVYDE/5-FU combination therapy for treating patients with pancreatic cancer. The Phase 1 portion of the study will examine increasing doses of XBiotech's new drug and assess the tolerability of the combination at escalating doses.
2021-04-19 04:00:00 - GlobeNewsWire
FDA Gives Go-Ahead for XBiotech's Candidate Therapy for Phase I/II Double-blind Placebo Controlled Study in Pancreatic Cancer
XBiotech's New Drug to Enter Clinical Studies in Combination Therapy for Pancreatic Cancer XBiotech's New Drug to Enter Clinical Studies in Combination Therapy for Pancreatic Cancer
2021-02-26 18:45:35 - Investopedia
Top Small-Cap Stocks for March 2021
These are the small-cap stocks with the best value, fastest growth, and most momentum for March 2021.